{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:27:12Z","timestamp":1778164032887,"version":"3.51.4"},"reference-count":89,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Generalitat Valenciana","award":["CIACIF\/2023\/234"],"award-info":[{"award-number":["CIACIF\/2023\/234"]}]},{"name":"European Social Fund","award":["CIACIF\/2023\/234"],"award-info":[{"award-number":["CIACIF\/2023\/234"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: The primary treatment of schizophrenia is pharmacotherapy with antipsychotic agents, such as risperidone and paliperidone. Population pharmacokinetic (PopPK) modelling plays a crucial role in optimising therapy by predicting of plasma concentrations, therapeutic efficacy, and the risk of adverse effects using model informed precision dosing. Objectives: This systematic review examined the PopPK models of risperidone and paliperidone in patients diagnosed with schizophrenia based on the available scientific evidence. Methods: A systematic review of the health science databases was conducted. The inclusion criteria were original articles published in peer-reviewed journals, studies focusing on the development of original PopPK models of risperidone and paliperidone, and clinical studies. The exclusion criteria were full-text articles that could not be retrieved; studies not including subjects diagnosed with schizophrenia or schizoaffective disorders; and studies that did not investigate risperidone or paliperidone. Results: A total of 19 studies developing PopPK models were analysed, including one- or two-compartment PopPK model structures. Interindividual variability in the pharmacokinetic parameters was shown to be influenced by factors such as CYP2D6 activity, renal function, body mass index, and sex. Parameter estimation revealed high variability in clearance and volume of distribution. Conclusion: Numerous PopPK models for risperidone and paliperidone have been published with a detailed characterisation of absorption, metabolism, and elimination. Therefore, future research should focus on the external validation of these models to facilitate their integration into clinical practice and optimise individualised dosing, ultimately improving treatment efficacy and safety across diverse patient populations.<\/jats:p>","DOI":"10.3390\/ph18050698","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T11:37:02Z","timestamp":1746704222000},"page":"698","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0483-3822","authenticated-orcid":false,"given":"Ana","family":"Carrascosa-Arteaga","sequence":"first","affiliation":[{"name":"School of Pharmacy, Miguel Hern\u00e1ndez University, 03550 San Juan de Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7183-6372","authenticated-orcid":false,"given":"Ricardo","family":"Nalda-Molina","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Miguel Hern\u00e1ndez University, 03550 San Juan de Alicante, Spain"},{"name":"Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0547-5975","authenticated-orcid":false,"given":"Patricio","family":"M\u00e1s-Serrano","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Miguel Hern\u00e1ndez University, 03550 San Juan de Alicante, Spain"},{"name":"Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), 03010 Alicante, Spain"},{"name":"Clinical Pharmacokinetics Unit, Pharmacy Department, Alicante University General Hospital, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-4743","authenticated-orcid":false,"given":"Amelia","family":"Ramon-Lopez","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Miguel Hern\u00e1ndez University, 03550 San Juan de Alicante, Spain"},{"name":"Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14712\/23362936.2024.10","article-title":"Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics","volume":"125","year":"2024","journal-title":"Prague Med. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","article-title":"Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly","volume":"34","author":"Biagi","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_3","first-page":"412","article-title":"Schizophrenia","volume":"117","author":"Hasan","year":"2020","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"ref_4","unstructured":"(2025, February 15). Overview. Psychosis and Schizophrenia in Adults: Prevention and Management. Guidance. NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/cg178."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2025, February 15). CIE-11 Para Estad\u00edsticas de Mortalidad y Morbilidad. Available online: https:\/\/icd.who.int\/browse\/2024-01\/mms\/en#1683919430."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.schres.2018.05.028","article-title":"Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study","volume":"201","author":"Melkote","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/nedt.2007.3.1.13","article-title":"Long-acting risperidone injection: Efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic","volume":"3","author":"Chue","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.9.1.9","article-title":"Use of long-acting risperidone in psychiatric disorders: Focus on efficacy, safety and cost\u2013effectiveness","volume":"9","author":"Keith","year":"2009","journal-title":"Expert. Rev. Neurother."},{"key":"ref_11","unstructured":"(2024, July 16). FT_PaliperidonaER. Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/83060\/83060%20ft.pdf."},{"key":"ref_12","unstructured":"(2024, July 16). Ficha T\u00e9cnica Risperidona Oral. Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/72920\/72920_ft.pdf."},{"key":"ref_13","unstructured":"(2025, February 15). Ficha T\u00e9cnica Palmitato de Paliperidona Suspension Inyectable. Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/86051\/86051_ft.pdf."},{"key":"ref_14","unstructured":"(2024, July 16). FT_RisperidalConsta. Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/65214\/FT_65214.pdf."},{"key":"ref_15","unstructured":"(2024, July 16). Ficha T\u00e9cnica OKEDI (Risperidona). Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220214154589\/anx_154589_es.pdf."},{"key":"ref_16","unstructured":"(2024, July 16). Risperidona_FT.pdf. Available online: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2004\/docs\/risperidona_FT.pdf."},{"key":"ref_17","unstructured":"(2025, February 15). BOTPLUS, Risperidona. Available online: https:\/\/botplusweb.farmaceuticos.com\/BInicio?txt=RISPERIDONA&opb=1&filtro=ESTADO__0&numMostrar=110&idxOrden=0."},{"key":"ref_18","unstructured":"(2025, February 15). BOTPLUS, Paliperidona. Available online: https:\/\/botplusweb.farmaceuticos.com\/BInicio?txt=palipeRIDONA."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jcph.295","article-title":"A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia","volume":"54","author":"Cleton","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_20","first-page":"1","article-title":"Dise\u00f1o de una formulaci\u00f3n parenteral para la liberaci\u00f3n prolongada de risperidona basada en un sistema de gelificaci\u00f3n in situ","volume":"36","author":"Peniche","year":"2017","journal-title":"Rev. Cuba. Investig. Biom\u00e9d."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20451253241280046","DOI":"10.1177\/20451253241280046","article-title":"Risperidone ISM\u00ae: Review and update of its usefulness in all phases of schizophrenia","volume":"14","author":"Messer","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/NDT.S3311","article-title":"Risperidone long-acting injection: A review of its long term safety and efficacy","volume":"4","author":"Rainer","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S53795","article-title":"Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia","volume":"7","author":"Kaplan","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2017.08.008","article-title":"Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics","volume":"39","author":"Pilon","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2011.06.029","article-title":"Long Acting Injection Versus Oral Risperidone in First-Episode Schizophrenia: Differential Impact on White Matter Myelination Trajectory","volume":"132","author":"Bartzokis","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/JCP.0000000000001484","article-title":"The Switch from Paliperidone Long-Acting Injectable 1- to 3-Monthly","volume":"42","author":"Mauri","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejphar.2008.02.005","article-title":"Using pharmacokinetic\u2013pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics","volume":"584","author":"Olsen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-007-0430-1","article-title":"Clinical utility of drug measurement and pharmacokinetics\u2014Therapeutic drug monitoring in psychiatry","volume":"64","author":"Hiemke","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction","volume":"22","author":"Spina","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1208\/s12248-010-9247-4","article-title":"Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms","volume":"13","author":"Maloney","year":"2011","journal-title":"AAPS J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/bcp.15260","article-title":"MAP Bayesian modeling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients","volume":"88","author":"Ismail","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.4088\/JCP.19cs13169","article-title":"Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/S0007114512001432","article-title":"Systematic reviews in nutrition: Standardized methodology","volume":"107","year":"2012","journal-title":"Br. J. Nutr."},{"key":"ref_41","first-page":"89","article-title":"Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products","volume":"50","author":"Gomeni","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s13318-024-00899-z","article-title":"Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II)","volume":"49","author":"Venkatasubramanian","year":"2024","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/11531730-000000000-00000","article-title":"Population Pharmacokinetics of Oral Risperidone in Children, Adolescents and Adults with Psychiatric Disorders","volume":"49","author":"Thyssen","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/psp4.12217","article-title":"Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone","volume":"6","author":"Korell","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.16115","article-title":"Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM\u00ae","volume":"90","author":"Laveille","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jcph.1842","article-title":"Modeling Complex Pharmacokinetics of Long-Acting Injectable Products Using Convolution-Based Models With Nonparametric Input Functions","volume":"61","author":"Gomeni","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40262-014-0132-7","article-title":"Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP-7000, a New Sustained-Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment","volume":"53","author":"Laffont","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2013.02.011","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility","volume":"146","author":"Kozielska","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40262-016-0459-3","article-title":"Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia","volume":"56","author":"Magnusson","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jcph.366","article-title":"Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone","volume":"55","author":"Laffont","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bcp.13246","article-title":"Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone","volume":"83","author":"Ivaturi","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40120-024-00578-w","article-title":"Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia","volume":"13","author":"Wang","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpdd.1078","article-title":"Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone","volume":"11","author":"Perlstein","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","article-title":"Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort","volume":"54","author":"Vandenberghe","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejps.2010.06.016","article-title":"A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia","volume":"41","author":"Locatelli","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jcph.141","article-title":"A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone","volume":"53","author":"Gomeni","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10928-006-9040-2","article-title":"Population Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Patients with Acute Episodes Associated with Bipolar I Disorder","volume":"34","author":"Vermeulen","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1248\/cpb.29.1410","article-title":"Studies on the absorption of practically water-insoluble drugs following injection. IV. An approach for predicting relative intramuscular absorption rates of a drug in oily solution, aqueous suspension and aqueous surfactant solution in rats","volume":"29","author":"Hirano","year":"1981","journal-title":"Chem. Pharm. Bull."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.clinthera.2007.07.026","article-title":"Plasma Pharmacokinetic Characteristics of Risperidone and Their Relationship to Saliva Concentrations in Children with Psychiatric or Neurodevelopmental Disorders","volume":"29","author":"Aman","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_62","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: A summary","volume":"55","author":"Heykants","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"Susce","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology"},{"key":"ref_66","first-page":"183","article-title":"The Human Cytochrome P450 Allele Nomenclature Committee Web Site: Submission Criteria, Procedures, and Objectives","volume":"320","author":"Sim","year":"2006","journal-title":"Methods Mol. Biol. Clifton"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17209","DOI":"10.1016\/S0021-9258(17)44890-3","article-title":"Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes","volume":"265","author":"Kagimoto","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side-effects","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s002280100372","article-title":"Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients","volume":"57","author":"Roh","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"Susce","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_72","unstructured":"(2025, February 14). Interactions M\u00e9dicamenteuses et Cytochromes P450. Available online: https:\/\/www.hug.ch\/sites\/interhug\/files\/structures\/pharmacologie_et_toxicologie_cliniques\/documents\/2002_29_4.pdf."},{"key":"ref_73","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_74","unstructured":"Ortho-McNeil-Janssen Pharmaceuticals, Inc (2025, February 15). Invega (Paliperidone) Extended Release Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021999s018lbl.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/schbul\/sbm161","article-title":"The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data","volume":"34","author":"Rabinowitz","year":"2008","journal-title":"Schizophr. Bull."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e31828f62cd","article-title":"Pharmacogenetic study on risperidone long-acting injection: Influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects","volume":"33","author":"Choong","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","article-title":"Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study","volume":"44","author":"Yoshimura","year":"2001","journal-title":"Neuropsychobiology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","article-title":"Long-term treatment of chronic schizophrenia with risperidone: A study with plasma levels","volume":"16","author":"Mauri","year":"2001","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":"Serum concentrations and side effects in psychiatric patients during risperidone therapy","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/DDDT.S17266","article-title":"Paliperidone extended-release: Does it have a place in antipsychotic therapy?","volume":"5","author":"Gahr","year":"2011","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1185\/03007995.2013.869201","article-title":"Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: Core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: The RISPALI study","volume":"30","author":"Gattaz","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","article-title":"Long-term effectiveness of flexibly dosed paliperidone extended-release: Comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents","volume":"29","author":"Kim","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite","volume":"21","author":"Melkersson","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: What is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.pnpbp.2010.07.003","article-title":"Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients","volume":"34","author":"Suzuki","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J. Psychiatr. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","article-title":"Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia","volume":"34","author":"Saito","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/698\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:29:45Z","timestamp":1760030985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ph18050698"],"URL":"https:\/\/doi.org\/10.3390\/ph18050698","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}